NCT06771986Completed
Soluble Advanced Glycation End Product (sRAGE) Levels
Soluble Advanced Glycation End Product (sRAGE) Levels in Childhood Obesity
Source: ClinicalTrials.gov · Last updated 13 Jan 2025
Brief summary (registry, in English)
The aim of this study is to evaluate sRAGE levels in children with obesity and to determine the relationship between metabolic status and sRAGE levels in childhood obesity
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 88 (actual)
- First submitted
- 3 Jan 2025
- Start date
- Feb 2023
- Primary completion date
- Aug 2023
- Lead sponsor
- Kayseri City Hospital
- Diseases
- Obesity
- NCT number
- NCT06771986
What you commit to
- Study type: Observational
- Participants enrolled: 88
- From Feb 2023 to the primary completion date, Aug 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes
Who the study is looking for
- Clinical diagnosis of Obesity BMI over 95th percentile BMI z-score over 2
Age in the registry: 10 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kayseri City Hospital Coordinator of this site? Confirm its status | Kayseri | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.